Articles

Small bowel villous atrophy due to immune-checkpoint inhibitors: report of two cases and literature review

Annalisa Schiepatti, Andrea Premoli, Stiliano Maimaris, Mimma Rizzo, Maria Marples, Laura Villani, Nigel Scott, Federico Sottotetti, David S Sanders, Federico Biagi, Clare Donnellan

Article Type

Case Report

Published

This article describes two cases of enteropathy with villous atrophy due to immune-checkpoint inhibitors, which may broaden the differential diagnosis of non-coeliac enteropathies and may represent a pathogenetic model for the understanding of the molecular mechanisms involved in these enteropathies. A narrative review is also provided, summarizing the current evidence on the adverse events of immune-checkpoint inhibitors involving the small bowel.

Read more

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain J Gelibter

Article Type

Review

Published

ALK-, ROS1- and NTRK-rearranged tumours represent a distinct clinical and molecular entity amongst non-small-cell lung cancer and have the highest frequency amongst young, non-smoker patients. This paper discusses ALK, ROS1 and NTRK-rearranged disease and all the available treatments are evaluated.

Read more

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors

Federico Sottotetti, Elisa Ferraris, Barbara Tagliaferri, Raffaella Palumbo, Erica Quaquarini, Cristina Teragni, Emanuela Balletti, Claudia Leli, Andrea Premoli, Ludovica Mollica, Silvia Puglisi, Silvia Sardi, Alberto Malovini, Paolo Pedrazzoli, Antonio Bernardo

Article Type

Original Research

Published

In this real-life study, the authors aim to evaluate the prognostic role of variations in cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) levels in patients with HR+/HER2− breast cancer treated with CDK4/6 inhibitors. The goal of this investigation is to consider whether it would be possible to use these markers as a monitoring tool to diagnose earlier, faster and in a more practical way.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.